SCHEMBL22355745

SCHEMBL22355745

C[C@@H]1CC[C@@]2(C(=O)n3cnc(-c4cccnc4)c3)CCC(C)(C)C[C@H]2CC(=O)/C=C2/[C@@]3(C)C=C(C#N)C(=O)C(C)(C)[C@@H]3CC[C@]21C

nearest known ligand 0.67

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ NOS2 P35228 8/20 0.67
▸ MBOAT4 Q96T53 4/20 0.46
▸ CCR6 P51684 1/20 0.46
▸ CYP3A4 P08684 2/20 0.39
▸ CYP2C19 P33261 2/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ KEAP1 Q14145 1/20 0.39
▸ NFE2L2 Q16236 3/20 0.38
▸ USP2 O75604 1/20 0.38
▸ STAT3 P40763 1/20 0.38
▸ USP7 Q93009 1/20 0.38
▸ RORC P51449 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24389441 0.84 NOS2 (0.78) NOS2MBOAT4CCR6CYP3A4CYP2C19
SCHEMBL24337267 0.80 NOS2 (1.00) NOS2MBOAT4CCR6CYP3A4CYP2C19
SCHEMBL22345144 0.80 NOS2 (1.00) NOS2MBOAT4CCR6CYP3A4CYP2C19
SCHEMBL17553177 0.80 NOS2 (1.00) NOS2MBOAT4CCR6CYP3A4CYP2C19
SCHEMBL23897712 0.80 NOS2 (1.00) NOS2MBOAT4CCR6CYP3A4CYP2C19
SCHEMBL26755395 0.78 NOS2 (0.85) NOS2MBOAT4CCR6CYP3A4CYP2C19
SCHEMBL19380279 0.74 NOS2 (1.00) NOS2MBOAT4CCR6CYP3A4CYP2C19
SCHEMBL24389445 0.73 NOS2 (0.77) NOS2MBOAT4CCR6CYP3A4CYP2C19
SCHEMBL17553178 0.73 NOS2 (1.00) NOS2MBOAT4CCR6CYP3A4CYP2C19
SCHEMBL26755157 0.73 NOS2 (1.00) NOS2MBOAT4CCR6CYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020167969-A1 METHODS AND COMPOSITIONS FOR INHIBITING THE NLRP3 INFLAMMASOME AND/OR LON PROTEASE TRITERPENOID THERAPEUTICS, INC. (US) 2020-08-20 — — WO disclosed
Send feedback